Abstract
Objective: Increased quinolinic acid (QA) accumulation has been found in many neurodegenerative diseases. Artemisia absinthium (A. absinthium) has been reported to have neuroprotective and antioxidant activities. This study was designed to evaluate the effect of A. absinthium in QAinduced neurotoxicity in OLN-93 Cells.
Methods: OLN-93 cells were cultured in a DMEM medium containing 10% (v/v) fetal bovine serum, 100 units/ml penicillin, and 100 μg/ml streptomycin. The cells were pretreated with concentrations of A. absinthium extract for two h and then exposed to QA for 24 h. After 24 h cell viability, the level of malondialdehyde (MDA), reactive oxygen species (ROS), and apoptotic cells were quantitated in OLN-93 Cells.
Results: Pretreatment with A. absinthium extract prevented the loss of cell viability in OLN-93 cells. ROS generation, lipid peroxidation, and apoptosis in QA-injured OLN-93 cells were reduced following A. absinthium extract pretreatment.
Conclusion: A. absinthium extract exerts its neuroprotective effect against QA-induced neurotoxicity via oxidative stress and apoptosis modulation.
Graphical Abstract
[1]
Ma S, Liu H, Jiao H, et al. Neuroprotective effect of ginkgolide K on glutamate-induced cytotoxicity in PC 12 cells via inhibition of ROS generation and Ca2+ influx. Neurotoxicology 2012; 33(1): 59-69.
[http://dx.doi.org/10.1016/j.neuro.2011.11.003] [PMID: 22120026]
[http://dx.doi.org/10.1016/j.neuro.2011.11.003] [PMID: 22120026]
[2]
Lugo-Huitrón R, Ugalde Muñiz P, Pineda B, Pedraza-Chaverrí J, Ríos C, Pérez-de la Cruz V. Quinolinic acid: an endogenous neurotoxin with multiple targets. Oxid Med Cell Longev 2013; 2013: 104024.
[http://dx.doi.org/10.1155/2013/104024]
[http://dx.doi.org/10.1155/2013/104024]
[3]
Batiha GES, Olatunde A, El-Mleeh A, et al. Bioactive compounds, pharmacological actions, and pharmacokinetics of wormwood] (Artemisia absinthium). Antibiotics 2020; 9(6): 353.
[http://dx.doi.org/10.3390/antibiotics9060353] [PMID: 32585887]
[http://dx.doi.org/10.3390/antibiotics9060353] [PMID: 32585887]
[4]
Shafi G, Hasan TN, Syed NA, et al. Artemisia absinthium (AA): A novel potential complementary and alternative medicine for breast cancer. Mol Biol Rep 2012; 39(7): 7373-9.
[http://dx.doi.org/10.1007/s11033-012-1569-0] [PMID: 22311047]
[http://dx.doi.org/10.1007/s11033-012-1569-0] [PMID: 22311047]
[5]
Boudjelal A, Ruberto G, Benkhaled A, Napoli E, Baali F. Phytochemical profile, antioxidant activity and wound healing properties of Artemisia absinthium essential oil. Asian Pac J Trop Biomed 2020; 10(11): 496.
[http://dx.doi.org/10.4103/2221-1691.294089]
[http://dx.doi.org/10.4103/2221-1691.294089]
[6]
Tariq KA, Chishti MZ, Ahmad F, Shawl AS. Anthelmintic activity of extracts of Artemisia absinthium against ovine nematodes. Vet Parasitol 2009; 160(1-2): 83-8.
[http://dx.doi.org/10.1016/j.vetpar.2008.10.084] [PMID: 19070963]
[http://dx.doi.org/10.1016/j.vetpar.2008.10.084] [PMID: 19070963]
[7]
Daradka HM, Abas MM, Mohammad MAM, Jaffar MM. Antidiabetic effect of Artemisia absinthium extracts on alloxan-induced diabetic rats. Comp Clin Pathol 2014; 23(6): 1733-42.
[http://dx.doi.org/10.1007/s00580-014-1963-1]
[http://dx.doi.org/10.1007/s00580-014-1963-1]
[8]
Rakhshandeh H, Heidari A, Pourbagher-Shahri AM, Rashidi R, Forouzanfar F. Hypnotic effect of A. absinthium hydroalcoholic extract in pentobarbital-treated mice. Neurol Res Int 2021; 2021: 5521019.
[9]
Amat N, Upur H, Blažeković B. In vivo hepatoprotective activity of the aqueous extract of Artemisia absinthium L. against chemically and immunologically induced liver injuries in mice. J Ethnopharmacol 2010; 131(2): 478-84.
[http://dx.doi.org/10.1016/j.jep.2010.07.023] [PMID: 20637853]
[http://dx.doi.org/10.1016/j.jep.2010.07.023] [PMID: 20637853]
[10]
Kaoudoune C, Benchikh F, Benabdallah H, Loucif K, Mehlous S, Amira S. Gastroprotective effect and in vitro antioxidant activities of the aqueous extract from Artemisia absinthium L Aerial parts. J Drug Deliv Ther 2020; 10(4): 153-6.
[http://dx.doi.org/10.22270/jddt.v10i4.4253]
[http://dx.doi.org/10.22270/jddt.v10i4.4253]
[11]
Mahmoudi M, Ebrahimzadeh M, Ansaroudi F, Nabavi S, Nabavi S. Antidepressant and antioxidant activities of Artemisia absinthium L. at flowering stage. Afr J Biotechnol 2009; 8(24): 7170-5.
[12]
Zeraati F, Esna-Ashari F, Araghchian M, et al. Evaluation of topical antinociceptive effect of Artemisia absinthium extract in mice and possible mechanisms. Afr J Pharm Pharmacol 2014; 8(19): 492-6.
[13]
Li F, Song X, Xu J, et al. Morroniside protects OLN-93 cells against H 2 O 2 -induced injury through the PI3K/Akt pathway-mediated antioxidative stress and antiapoptotic activities. Cell Cycle 2021; 20(7): 661-75.
[http://dx.doi.org/10.1080/15384101.2021.1889186] [PMID: 33734020]
[http://dx.doi.org/10.1080/15384101.2021.1889186] [PMID: 33734020]
[14]
Richter-Landsberg C, Heinrich M. OLN-93: A new permanent oligodendroglia cell line derived from primary rat brain glial cultures. J Neurosci Res 1996; 45(2): 161-73.
[http://dx.doi.org/10.1002/(SICI)1097-4547(19960715)45:2<161:AID-JNR8>3.0.CO;2-8] [PMID: 8843033]
[http://dx.doi.org/10.1002/(SICI)1097-4547(19960715)45:2<161:AID-JNR8>3.0.CO;2-8] [PMID: 8843033]
[15]
Forouzanfar F, Asadpour E, Hosseinzadeh H, et al. Safranal protects against ischemia-induced PC12 cell injury through inhibiting oxidative stress and apoptosis. Naunyn Schmiedebergs Arch Pharmacol 2021; 394(4): 707-16.
[http://dx.doi.org/10.1007/s00210-020-01999-8] [PMID: 33128592]
[http://dx.doi.org/10.1007/s00210-020-01999-8] [PMID: 33128592]
[16]
Rashidi R, Ghorbani A, Rakhshandeh H, Mousavi SH. Protective effect of Artemisia absinthium on 6-hydroxydopamine-induced toxicity in SH-SY5Y cell line. Avicenna J Phytomed 2021; 11(3): 238-46.
[PMID: 34046320]
[PMID: 34046320]
[17]
Rahman MH, Akter R, Kamal MA. Prospective function of different antioxidant containing natural products in the treatment of neurodegenerative diseases. CNS Neurological Disorders-Drug Targets 2021; 20(8): 694-703.
[18]
Welz AN, Emberger-Klein A, Menrad K. Why people use herbal medicine: Insights from a focus-group study in Germany. BMC Complement Altern Med 2018; 18(1): 92.
[http://dx.doi.org/10.1186/s12906-018-2160-6] [PMID: 29544493]
[http://dx.doi.org/10.1186/s12906-018-2160-6] [PMID: 29544493]
[19]
Srivastava A, Srivastava P, Pandey A, Khanna V, Pant A. Phytomedicine: A potential alternative medicine in controlling neurological disorders New Look to Phytomedicine. Elsevier 2019; pp. 625-55.
[20]
Sadeghnia HR, Jamshidi R, Afshari AR, Mollazadeh H, Forouzanfar F, Rakhshandeh H. Terminalia chebula attenuates quinolinate-induced oxidative PC12 and OLN-93 cell death. Mult Scler Relat Disord 2017; 14: 60-7.
[http://dx.doi.org/10.1016/j.msard.2017.03.012] [PMID: 28619434]
[http://dx.doi.org/10.1016/j.msard.2017.03.012] [PMID: 28619434]
[21]
Sas K, Robotka H, Toldi J, Vécsei L. Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders. J Neurol Sci 2007; 257(1-2): 221-39.
[http://dx.doi.org/10.1016/j.jns.2007.01.033] [PMID: 17462670]
[http://dx.doi.org/10.1016/j.jns.2007.01.033] [PMID: 17462670]
[22]
Hestad K, Alexander J, Rootwelt H, Aaseth JO. The role of tryptophan dysmetabolism and quinolinic acid in depressive and neurodegenerative diseases. Biomolecules 2022; 12(7): 998.
[http://dx.doi.org/10.3390/biom12070998] [PMID: 35883554]
[http://dx.doi.org/10.3390/biom12070998] [PMID: 35883554]
[23]
Yong HYF, Yong VW. Mechanism-based criteria to improve therapeutic outcomes in progressive multiple sclerosis. Nat Rev Neurol 2022; 18(1): 40-55.
[http://dx.doi.org/10.1038/s41582-021-00581-x] [PMID: 34732831]
[http://dx.doi.org/10.1038/s41582-021-00581-x] [PMID: 34732831]
[24]
Pegoretti V, Swanson KA, Bethea JR, Probert L, Eisel UL, Fischer R. Inflammation and oxidative stress in multiple sclerosis: Consequences for therapy development. Oxidative medicine and cellular longevity 2020; 2020: 7191080.
[http://dx.doi.org/10.1155/2020/7191080]
[http://dx.doi.org/10.1155/2020/7191080]
[25]
Ohl K, Tenbrock K, Kipp M. Oxidative stress in multiple sclerosis: Central and peripheral mode of action. Exp Neurol 2016; 277: 58-67.
[http://dx.doi.org/10.1016/j.expneurol.2015.11.010] [PMID: 26626971]
[http://dx.doi.org/10.1016/j.expneurol.2015.11.010] [PMID: 26626971]
[26]
Craciunescu O, Constantin D, Gaspar A, Toma L, Utoiu E, Moldovan L. Evaluation of antioxidant and cytoprotective activities of Arnica montana L. and Artemisia absinthium L. ethanolic extracts. Chem Cent J 2012; 6(1): 97.
[http://dx.doi.org/10.1186/1752-153X-6-97] [PMID: 22958433]
[http://dx.doi.org/10.1186/1752-153X-6-97] [PMID: 22958433]
[27]
Hadi A, Hossein N, Shirin P, Najmeh N, Abolfazl M. Anti-inflammatory and analgesic activities of Artemisia absinthium and chemical composition of its essential oil. Int J Pharm Sci Rev Res 2014; 38: 237-44.
[28]
Bora KS, Sharma A. Neuroprotective effect of Artemisia absinthium L. on focal ischemia and reperfusion-induced cerebral injury. J Ethnopharmacol 2010; 129(3): 403-9.
[http://dx.doi.org/ 10.1016/j.jep.2010.04.030 ] [PMID: 20435123]
[http://dx.doi.org/ 10.1016/j.jep.2010.04.030 ] [PMID: 20435123]
